March 2, 2018
BMS welcomes new Board member
Bristol-Myers Squibb’s Board of Directors has elected José Baselga, M.D., Ph.D., to the Board, effective March 1, 2018. Dr. Baselga will…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
March 1, 2018
(EDITED) Vertex kicks off phase 3 trial of triple combination regimen for people with the most common genetic form of Cystic Fibrosis
Edit: The first paragraph used to say: Vertex is conducting the global ECLIPSE Phase 3 clinical trial program to evaluate VX-659…
March 1, 2018
Novavax plans Phase 2 trial of NanoFlu vaccine in third quarter of 2018
NanoFlu vaccine was well tolerated over the three-week trial period, Novavax said Thursday, adding it now expects to begin a…
March 1, 2018
Amarin Corporation’s cardiovascular study is nearing completion
Amarin Corporation’s REDUCE-IT cardiovascular study is nearing end, as the patients enrolled in it have begun the final study-related visits.
March 1, 2018
Basilea Pharmaceutica names Kaul as its Management Committee’s Chief Development Officer
Basilea Pharmaceutica has named Adesh Kaul as its Management Committee’s Chief Corporate Development Officer, who has been leading partnering activities…
March 1, 2018
Novartis and Pear Therapeutics work on prescription digital therapeutics for patients with schizophrenia and multiple sclerosis
Novartis and Pear Therapeutics will develop new treatments for patients with schizophrenia and multiple sclerosis, with Pear’s prescription digital therapeutics…
March 1, 2018
Gelesis bags $30 million to prepare for regulatory approval of its weight loss capsules
PureTech Health’s affiliate Gelesis has rasied $30 million to back bringing closer to shelves its pipeline of additinoal gastrointestinal disorders product candidates,…
February 28, 2018
EMA grants accelerated assessment for Shire’s Lanadelumab being evaluated for the prevention of attacks in Hereditary Angioedema patients aged 12 years and older
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment for…
February 28, 2018
Novo Nordisk files for regulatory approval in the US and the EU for treatment of haemophilia A
Novo Nordisk has submitted a Biologics License Applications (BLA) to the US Food and Drug Administration (FDA) and a Marketing…
February 28, 2018
FDA rejects Celgene’s NDA for multiple sclerosis treatment
Celgene Corporation (NASDAQ:CELG) has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug…